Alliance Pharma Regulatory News (APH)

For immediate release

2 July 2021

Name of applicant:

ALLIANCE PHARMA PLC

Names of schemes:

a) The Alliance Pharma plc Approved Share Option Plan 2005

b) The Alliance Pharma plc Share Option Plan 2006

c) The Alliance Pharma plc Company Share Option Plan 2015

Period of return:

From:

28 December 2020

To:

28 June 2021

Number of securities originally admitted at date of admission:

25,000,000 ordinary shares of 1p each

28 June 2017

Balance of unallotted securities under schemes from previous return:

a) 293,372

b) 5,266,622

c) 13,265,746

Plus: The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):

a) Nil

b) Nil

c) Nil

Less: Number of securities issued/allotted under schemes during period:

a) 258,052

b) 317,909

c) 1,816,189

Equals: Balance under schemes not yet issued/allotted at end of period:

d) 35,320

e) 4,948,713

f) 11,449,557

Name of contact:

Chris Chrysanthou, Company Secretary

Telephone number of contact:

Tel. +44 (0)1249 705166

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele

Corporate Broking: James Black

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

Corporate Broking: Patrick Robb